Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04198766 · ClinicalTrials.gov registry record · Phase 1
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Inhibrx Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 296
- Enrollment target
- 20
- Study locations
NCT04198766 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by Inhibrx Biosciences. The registered enrollment target is 296 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04198766, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by Inhibrx Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 296 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Conditions Studied
Interventions
- DRUG INBRX-106 - Hexavalent OX40 agonist antibody
- DRUG pembrolizumab 200 mg
- DRUG pembrolizumab 400 mg
- DRUG Carboplatin AUC-5
- DRUG Carboplatin AUC-6
Study Locations (20)
California
- City of Hope - Duarte
- Los Angeles Cancer Network - Glendale
- California Research Institute - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Valkyrie Clinical Trials - Murrieta
- Providence Medical Foundation - Santa Rosa
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
- Henry Ford Cancer Institute - Detroit
- START Midwest - Grand Rapids
Florida
- Clermont Oncology Center - Clermont
- Mid Florida Hematology and Oncology Center - Orange City
Minnesota
- HealthPartners Cancer Research Center - Saint Louis Park
- HealthPartners Cancer Research Center (Regions Hospital) - Saint Paul
Georgia
- Winship Cancer Institute - Emory University - Atlanta
Illinois
- The University of Chicago Medical Center - Chicago
Iowa
- University of Iowa - Iowa City
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2027-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04198766
The ClinicalTrials.gov registry entry for NCT04198766 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Inhibrx Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which INBRX-106 - Hexavalent OX40 agonist antibody is the first listed.
NCT04198766 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT04198766 about?
NCT04198766 is a clinical study titled "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)". This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab...
What is the current status of trial NCT04198766?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 296 participants. The study started on 2019-12-10. Estimated completion is 2027-05-12.
What conditions does trial NCT04198766 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Solid Tumor, Gastric Cancer.
What interventions are being tested in trial NCT04198766?
The interventions under investigation include: INBRX-106 - Hexavalent OX40 agonist antibody (DRUG), pembrolizumab 200 mg (DRUG), pembrolizumab 400 mg (DRUG), Carboplatin AUC-5 (DRUG), Carboplatin AUC-6 (DRUG).
Who is sponsoring clinical trial NCT04198766?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04198766 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.